These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24914397)

  • 21. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment.
    Seet RC; Rabinstein AA
    QJM; 2012 Jan; 105(1):69-75. PubMed ID: 21865314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversible posterior leukoencephalopathy syndrome induced by vinorelbine.
    Chen YH; Huang CH
    Clin Breast Cancer; 2012 Jun; 12(3):222-5. PubMed ID: 22424944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab.
    Peter S; Hausmann N; Schuster A; Boehm HF
    Clin Exp Ophthalmol; 2008; 36(1):94-6. PubMed ID: 18290962
    [No Abstract]   [Full Text] [Related]  

  • 24. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
    Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
    Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
    [No Abstract]   [Full Text] [Related]  

  • 25. [Posterior Reversible Encephalopathy Syndrome (PRES): About 4 cases].
    Chanal E; Bouleftour W; Rivoirard R; Bosaki C; Forges F; Jacquin JP; Fournel P; Mery B; Saban-Roche L
    Presse Med; 2019 Oct; 48(10):1026-1031. PubMed ID: 31653541
    [No Abstract]   [Full Text] [Related]  

  • 26. Reversible posterior leukoencephalopathy syndrome due to adrenal pheochromocytoma: A case report and literature review.
    Han B; Li Y; Tang M; Wu S; Xu X
    Medicine (Baltimore); 2020 Jul; 99(28):e20918. PubMed ID: 32664087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin.
    Sharief U; Perry DJ
    Clin Colorectal Cancer; 2009 Jul; 8(3):163-5. PubMed ID: 19632931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversible posterior leukoencephalopathy syndrome induced by pazopanib.
    Chelis L; Souftas V; Amarantidis K; Xenidis N; Chamalidou E; Dimopoulos P; Michailidis P; Christakidis E; Prassopoulos P; Kakolyris S
    BMC Cancer; 2012 Oct; 12():489. PubMed ID: 23088634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature.
    Rajasekhar A; George TJ
    Oncologist; 2007 Nov; 12(11):1332-5. PubMed ID: 18055853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversible posterior leukoencephalopathy syndrome in children with nephrotic syndrome: a case report.
    Liu SD; Shen QM; Lv CF
    Chin Med Sci J; 2014 Mar; 29(1):55-7. PubMed ID: 24698681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs.
    Marinella MA; Markert RJ
    Intern Med J; 2009 Dec; 39(12):826-34. PubMed ID: 19220526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A case of reversible posterior leukoencephalopathy syndrome(RPLS)induced by modified FOLFOX6].
    Matsunaga M; Miwa K; Araki K; Sunakawa Y; Yamashita K; Kaneta T; Nakayama H; Noguchi T; Nagashima F; Sasaki Y
    Gan To Kagaku Ryoho; 2012 Aug; 39(8):1283-6. PubMed ID: 22902460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical spectrum of reversible posterior leukoencephalopathy syndrome.
    Lee VH; Wijdicks EF; Manno EM; Rabinstein AA
    Arch Neurol; 2008 Feb; 65(2):205-10. PubMed ID: 18268188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy.
    Ozkan A; Hakyemez B; Ozkalemkas F; Ali R; Ozkocaman V; Ozcelik T; Taskapilioglu O; Altundal Y; Tunali A
    Neuroradiology; 2006 Dec; 48(12):887-92. PubMed ID: 16983525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer.
    Sclafani F; Giuseppe G; Mezynksi J; Collins C; Crown J
    J Clin Oncol; 2012 Sep; 30(26):e257-9. PubMed ID: 22649141
    [No Abstract]   [Full Text] [Related]  

  • 36. Posterior reversible encephalopathy syndrome associated with deoxycoformycin and alemtuzumab.
    Cooksley T; Haji-Michael P
    J R Coll Physicians Edinb; 2011 Sep; 41(3):215-7. PubMed ID: 21949916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab.
    Palma JA; Gomez-Ibañez A; Martin B; Urrestarazu E; Gil-Bazo I; Pastor MA
    Neurologist; 2011 Sep; 17(5):273-5. PubMed ID: 21881470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.
    Lièvre A; Samalin E; Mitry E; Assenat E; Boyer-Gestin C; Lepère C; Bachet JB; Portales F; Vaillant JN; Ychou M; Rougier P
    BMC Cancer; 2009 Sep; 9():347. PubMed ID: 19785749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benign reversible encephalopathy syndrome after bevacizumab therapy for metastatic ovarian cancer.
    Sawaya R; Radwan W; Hammoud S
    Med Oncol; 2014 Feb; 31(2):831. PubMed ID: 24385223
    [No Abstract]   [Full Text] [Related]  

  • 40. [A case of colon cancer with reversible posterior leukoencephalopathy syndrome following 5-FU and oxaliplatin (FOLFOX regime)].
    Nagata Y; Omuro Y; Shimoyama T; Sasaki E; Okamoto R; Maeda Y; Kishida S; Sasaki T
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1163-6. PubMed ID: 19620809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.